Jasper Therapeutics regains Nasdaq minimum bid price compliance

Jasper Therapeutics, Inc.

Received Nasdaq letter on Jan 18, 2023 confirming full compliance with Listing Rule 5550(a)(2).
Closing bid price of voting common stock was $1.00 or higher for ten consecutive days (Jan 3-17, 2023).
Compliance removes risk of delisting from Nasdaq Capital Market.

item 8.01 item 9.01

Jasper Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-003597

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.